This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALQA Alliqua Biomedical (ALQA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Alliqua Biomedical Stock (NASDAQ:ALQA) 30 days 90 days 365 days Advanced Chart Get Alliqua Biomedical alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.20▼$3.2352-Week Range N/AVolume371,516 shsAverage Volume114,400 shsMarket Capitalization$13.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAlliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It also provides contract manufacturing services to the OEM market. The company is headquartered in Langhorne, Pennsylvania.Read More… Receive ALQA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alliqua Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address ALQA Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com ALQA Stock Analysis - Frequently Asked Questions How were Alliqua Biomedical's earnings last quarter? Alliqua Biomedical Inc (NASDAQ:ALQA) posted its earnings results on Tuesday, August, 9th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of ($2.70) by $3.20. The firm had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.38 million. Alliqua Biomedical had a negative trailing twelve-month return on equity of 71.73% and a negative net margin of 230.50%. When did Alliqua Biomedical's stock split? Alliqua Biomedical's stock reverse split before market open on Friday, October 6th 2017. The 1-10 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Alliqua Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alliqua Biomedical investors own include Palatin Technologies (PTN), ContraVir Pharmaceuticals (CTRV), Argos Therapeutics (ARGSQ), Consolidated Water (CWCO), Bristol-Myers Squibb (BMY), Biopharmx (BPMX) and Ritter Pharmaceuticals (RTTR). Company Calendar Last Earnings8/09/2016Today5/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:ALQA CIK1054274 Webwww.alliqua.com Phone215-702-8550FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,420,000.00 Net Margins-230.50% Pretax MarginN/A Return on Equity-71.73% Return on Assets-55.23% Debt Debt-to-Equity RatioN/A Current Ratio8.28 Quick Ratio8.17 Sales & Book Value Annual Sales$2.22 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / BookN/AMiscellaneous Outstanding Shares5,010,000Free FloatN/AMarket Cap$13.46 million OptionableNot Optionable Beta2.03 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ALQA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alliqua Biomedical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alliqua Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.